We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Tarsus Group Plc | TRS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 424.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 424.00 |
| Top Posts |
|---|
Posted at 07/9/2015 09:16 by battlebus2 Well he's certainly brought Tarsus to the attention of a few other investors. |
Posted at 30/10/2012 14:56 by robobhoy We've made it!Tarsus has been tipped in the Mail on Sunday!! Perhaps some sophisticated investors will now jump on......if only for the excellent dividends. |
Posted at 25/10/2012 18:58 by woodcutter robI think investors may be put off by the large swings in earnings from one year to the next, and many aren't patient enough to see the long term value. On the liquidity, i like small share based businesses provided they are niche and have good prospects. Many of my holdings have an even lower share base, it's usually turned out okay for me but you're right in the sense that if it goes wrong it can be difficult to liquidate your holdings. I have been doing it for a long long time and so far, for me, it's been fine. WC |
Posted at 25/10/2012 18:46 by robobhoy You may be right and i hope that you are.The problem for sizeable holders is the liquidity of the shares. There's only about 800 or so shareholders in the company and this is a problem. If investors can't understand the nature of a biennial event then perhaps they shouldn't be thinking about putting their money anywhere else other than the post office! |
Posted at 17/10/2012 09:31 by woodcutter bought a few more this morning and have now probably seen my last top up, my holding is quite reasonable for the size of my portfolio now so it's sit back and observe time. i might be persuaded to take on more if the next results are outstanding.My view fwiw is the business is very much misunderstood due to the biennial nature of many of it's contracts and as such i think it's glossed over by many investors and also undervalued. The continuing growth in higher margin emerging markets is a move which i think will ultimately, over the coming years, prove beneficial to those who are prepared to be patient as at some point i think the wider investment community will catch on to the value here. Woody |
Posted at 25/10/2010 10:06 by share_shark Yes, well it has excellent write up in Momentum Investor this weekend. Not a holder afraid. ;-(((( GLA |
Posted at 05/3/2010 08:33 by billbyrne This looks to be a very good appointment. Lets hope he can drive theAsia business forward as he did at UBM. RNS Number : 1168I Tarsus Group PLC 05 March 2010 ? 5 March 2010 Tarsus Group plc Appointment of new CEO for Asia * Highly experienced CEO appointed to drive growth in Asia * Continued development of business infrastructure within the Group * Based in new Hong Kong office - local knowledge in local markets Tarsus Group plc ('Tarsus' or 'the Group'), the international business-to-business media group, is pleased to announce the appointment of Gary Marshall, 52, to the Board as CEO Asia with effect from 31 March 2010. Gary spent 11 years at United Business Media ('UBM') where for six years he was CEO of their Asian B2B business. He led the business from its small initial base and built it into one of the leading Asian international exhibition organisers through an active organic and acquisition strategy. Based in Hong Kong, the business developed a significant presence in Asia including a leading position in China. Following UBM's $920 million acquisition of CMP Media in 2000 Gary relocated to New York to become President and CEO of CMP Media and Chairman of the Asia operations. He left UBM in 2005 and then joined IDG Inc., the world's leading technology media, events and research company, as Director of International Business Development. At IDG he focused primarily on building their Asian and Middle Eastern businesses. Neville Buch, Chairman of Tarsus, commented: "Tarsus' Emerging Markets division continues to grow strongly and constituted a third of Group revenues in 2009. This growth has been underpinned by the creation of the vital business infrastructure that is required to support expansion in the region. We are therefore pleased to be able to announce Gary's appointment to the Board as the latest development in this key element of our strategy. His proven track record in the exhibition industry and depth of international business experience, particularly within Asia and the Middle East, will accelerate our growth in Asia going forward and be a key asset in pursuit of our Project 50/13 growth strategy."* The Company confirms that there is no further information required by Listing Rule 9.6.13R to be disclosed in relation to Gary Marshall. *Note for Editors: The Project 50/13 growth strategy refers to the Group's recently stated intention to source 50% of revenues from emerging economies by 2013. Tarsus Group plc: Douglas Emslie, Group Managing Director 020 8846 2700 Ashley Milton, Group Finance Director 020 8846 2700 Investors/Analysts: Scott Harris Stephen Scott, Jeremy Wiseman 020 7653 0030 This information is provided by RNS The company news service from the London Stock Exchange END |
Posted at 13/8/2009 12:11 by investinggarden Buy recommendation from Growth Company Investor |
Posted at 12/11/2007 23:22 by harko12 Strategic acquisition in fast growing Dubai market and New Joint VentureTARSUS GROUP PLC New Joint Venture 12 November 2007 Tarsus Group plc, the international business-to-business media group with interests in exhibitions, conferences, publishing and on-line media, has today announced the formation of a new joint venture in France. On 5th September 2007 Tarsus announced the acquisition of SEPIC which is the owner and operator of the Midec and Mod'Amont exhibitions in Paris. Mod'Amont is the leading international exhibition for clothing accessories and is co-located with the pre-eminent international textile exhibition Premiere Vision. Tarsus and Premiere Vision will now form a joint venture to run Mod'Amont and Premiere Vision will acquire 49% of the exhibition for 3.5million for cash. Completion is expected to take place in January 2008. In addition, the joint venture has entered into an agreement to share marketing and operating services at their co-located events and it is planned to replicate the Mod'Amont exhibition alongside Premiere Vision internationally. The directors of Tarsus continue to anticipate that the acquisition of SEPIC will be earnings enhancing in the year to 31 December 2008. Douglas Emslie, Group Managing Director of Tarsus said: "Mod'Amont and Premiere Vision are complementary exhibitions and the formation of the joint venture will further their potential both in the important French market and internationally". For further information, please contact: Tarsus Group plc: Douglas Emslie, Group Managing Director: 020 7593 4000 Media: Matthew Moth, Madano Partnership: 020 7593 4000 Investors/Analysts: Neville Harris, IRfocus: 020 7593 4215 Tarsus Group PLC 12 November 2007 TARSUS GROUP PLC Strategic acquisition in fast growing Dubai market 12 November 2007 Tarsus Group plc, the international business-to-business media group with interests in exhibitions, conferences, publishing and on-line media, has today announced the acquisition of 100% of the share capital of The WR Kern Organisation Limited, the UK based holding company of Fairs and Exhibitions (1992) Ltd ("F&E"), its sole operating company. F&E was founded in 1958 and has been focused on the Middle East since 1976. It is one of the largest exhibition organisers in Dubai with 8 events covering three principal industry sectors:- aviation, printing & packaging and education, covering approximately 50,000 net square metres in total. Tarsus will pay an initial cash consideration of US$23.5 million (approximately £11.3 million). A further sum of up to US$11.5 million (approximately £5.5 million) may be payable in cash based on the future performance of the business over the period to 30 April 2009. The existing management team will remain in place to conduct the day-to-day running of the business. A significant proportion of F&E's revenue is derived from the biennial Dubai Airshow which takes place on 11th-15th November 2007, its tenth edition anniversary. This event has some 900 exhibiting companies occupying over 32,000 net square metres and is expecting more than 40,000 trade visitors. Strong growth in participation and revenue are anticipated to result from a move to a new and larger dedicated venue in 2009. Owing to the biennial nature of the F&E business, this acquisition is expected to be earnings enhancing in the current year and also over the biennial cycle of 2008 and 2009. Douglas Emslie, Group Managing Director of Tarsus, said: "Tarsus has continued to make good progress in the second half of the year and contracted revenue now stands at 97% of our full year forecast. This acquisition presents Tarsus with a unique opportunity to accelerate our strategy of expansion into fast growing markets. It will also allow us to extend our core brands into a new geographic territory. The world renowned Dubai Airshow is now Tarsus' largest event and immediately gives us scale and exposure in the Middle East. This region, and in particular Dubai, is expected to benefit further in the future from new exhibition venues and infrastructure developments. Opportunities to purchase exhibition companies of meaningful size in this region are scarce and F&E, with its long established management and definitive products, is rare. It is our intention to focus on Dubai as we develop our business in the Middle East under the existing management of Virginia Kern and the F&E team. We particularly look forward to working with the Department of Civil Aviation in Dubai to further strengthen the aviation portfolio to the benefit of the dynamic Dubai economy". For further information, please contact: Tarsus Group plc: Douglas Emslie, Group Managing Director: 020 7593 4000 Media: Matthew Moth, Madano Partnership: 020 7593 4000 Investors/Analysts: Neville Harris, IRfocus: 020 7593 4215 |
Posted at 16/11/2006 11:09 by ian.g ...and now we know the reason for the rise - another smaller conference organiser bought, as TRS continue to consolidate their position:16 November 2006 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, REPUBLIC OF SOUTH AFRICA, REPUBLIC OF IRELAND OR JAPAN Tarsus Group plc Acquisition of Medical Conferences International Inc. and Vendor Placing Tarsus Group plc ("Tarsus" or "the Company") (LSE: TRS), the international media group with interests in exhibitions, conferences, publishing and online media, is pleased to announce that it has agreed to acquire 80% of the issued share capital of Medical Conferences International Inc. ("MCII") (the "Acquisition") from Dr. Robert Goldman MD, PhD, DO, FAASP, and Dr. Ronald Klatz MD, DO (the "Vendors"). The total consideration for the Acquisition is US$46.0 million plus an amount equal to the net assets of MCII on completion which is estimated to be US$3.0 million. US$36.0 million (approximately #19.1 million) of the consideration is payable to the Vendors in cash on completion (the "initial consideration") and up to a further US$10 million is payable as deferred consideration. The deferred consideration is payable over up to five years subject to certain performance criteria relating to the level of growth achieved by MCII over a 5 year period. The payment for MCII's net assets is payable in cash following preparation of completion accounts. The Company is also pleased to announce that KBC Peel Hunt Ltd ("KBC Peel Hunt") has conditionally placed 5,304,107 new ordinary shares of 5p each in the Company ("Ordinary Shares") by way of a vendor placing to raise approximately #11.0 million to partially fund the initial consideration (the "Vendor Placing"). The Vendor Placing has been fully underwritten by KBC Peel Hunt. Further, the Company has today extended its existing bank facility with Royal Bank of Scotland by #10 million, repayable over a 5 year period, to fund the balance of the initial consideration. In the year to 31 December 2005, MCII's unaudited turnover was US$3.9 million, adjusted profits before tax was US$1.7 million and gross assets were US$1.9 million. The Vendors have warranted that adjusted pre-tax profits for the year to 31 December 2006 will be not less than US$5.5 million. Completion of the Acquisition is conditional, inter alia, on completion of the Vendor Placing, which is expected to occur on 21 November 2006. Information on MCII MCII, founded in 2003 by Dr Goldman and Dr Klatz, owns and operates the three leading medical sector exhibitions and conferences in the US anti-ageing market which take place annually in Orlando (April), Chicago (July) and Las Vegas (December). The upcoming event in December 2006 is expected to be attended by at least 5,000 doctors and healthcare professionals, and for many of them will contribute towards ongoing professional accreditation. MCII has been expanding the brand internationally using joint venture partners and 27 small conferences worldwide are scheduled for 2007. Dr Robert Goldman (aged 51) is the Chairman of the American Academy of Anti-Ageing Medicine ("A4M") and (with Dr Ronald Klatz) the Founding President of the National Academy of Sports Medicine, USA. He has spearheaded the development of numerous international medical organizations and corporations and has received a number of awards including the International Olympic Committee Tribute Diploma for the Development of Sport and Olympism and the Global Medal for Science. He is currently Chairman of the International Medical Commission overseeing sports medicine committees in over 176 nations. He visits an average of 20 countries annually to promote brain research and sports medicine programmes. Dr Ronald Klatz (aged 51) is the developer or administrator for over 100 scientific patents and has received a number of awards in recognition. In his capacity as A4M president, he oversees continuing medical programmes for more than 11,500 physicians, health practitioners and scientists worldwide. He has published a number of books in the anti-ageing field and numerous articles in related journals. He is a respected advisor to several members of the US Congress and devotes much of his time to research. Dr. Goldman and Dr. Klatz will remain with the business, on substantially similar terms and conditions as prior to the Acquisition, to continue to drive its expansion. Background to the anti-ageing market Anti-ageing medicine is a fast growing clinical medical specialty and an extension of preventive health care and is based on the early detection, prevention, and reversal of ageing-related diseases and aesthetic procedures. Alzheimer's disease, cataracts, prostate and skin cancer, impotence, osteoporosis and dementia and cosmetic and transplant surgery are just some examples of such diseases and procedures. With early detection and appropriate intervention, many diseases can be prevented, cured, or have their downward course reversed. The science is multi-disciplinary covering not only established fields like biochemistry, biology, and physiology, but extending into mind/body medicine, sports medicine, molecular genetics, and emerging medical technologies. In 2005, the Business Communications Company Inc. (a US research company) estimated that turnover in the US anti-ageing medical marketplace would reach some $49 billion in 2005 and would grow to some $72 billion by 2009, a compound growth rate of 10% p.a. Building on Tarsus's growing core business, which is currently trading in line with management's expectations, the Acquisition provides Tarsus with a new business division in a fast growing market. Tarsus now has five business divisions covering seven market sectors. Tarsus's current sales, operating and administrative infrastructure will strengthen MCII's market position and together MCII's conferences and exhibitions are expected to expand rapidly, with their main focus being in the United States. The Acquisition will increase Tarsus's scale and will therefore provide it with a broader and more diversified business. The Board believes that the Acquisition will be earnings per share enhancing in the current financial year and first full year of ownership. Commenting on the Acquisition, Douglas Emslie, Group Managing Director of Tarsus, said: "We are delighted to be able to acquire MCII at this early stage of its development. MCII has already shown its ability to grow and is in a sector of the medical market which is itself expanding rapidly. This acquisition takes Tarsus into a fast growing area and further broadens the number of sectors we serve." Vendor Placing Part of the initial consideration for the Acquisition will be satisfied by a Vendor Placing to raise approximately #11.0 million (#10.5 million net of expenses in relation to the Vendor Placing and the Acquisition). KBC Peel Hunt as agent for the Company, has conditionally placed 5,304,107 Ordinary Shares representing 9.9% of the existing issued share capital of the Company with institutional investors (the "Placing Shares") at a placing price of 207p per new Ordinary Share (the "Placing Price"). The Placing Price represents a discount of 3.6% to the closing mid-market price of 214.625p per share on 15 November 2006. The Placing Shares will be issued credited as fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive any future dividends and other distributions. The Acquisition and the Vendor Placing, which has been fully underwritten by KBC Peel Hunt, are conditional on Admission. Attention is drawn to the detailed terms and conditions of the Vendor Placing described in the appendix to this announcement. Application will be made for admission of the Placing Shares to the Official List of the United Kingdom Listing Authority and to trading on London Stock Exchange plc's market for listed securities ("Admission") and it is expected that dealings in the Placing Shares will commence at 8.00 a.m. on 21 November 2006. ...... Note that this is expected to be earnings enhancing in the current financial year and also earnings per share enhancing in the current financial year. The share price is now well clear of the previous high, and just on the chart basis should continue to rise in the short term to around 260. But the business is now bigger and has prospects for even faster growth, so a further rerating may be in order. Has anyone else even noticed? Cheers, Ian |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
